Unilife Signs Commercial Supply Agreement with MedImmune, page-68

Regardless of Hank's position, the statement is entirely correct. As is usually the case, there is a huge amount of misinformation on these threads.

The simple fact of the matter is as follows:
a) This ann. is an extension to an existing agreement, and simply formalises what was already known - that commercial qtys were to be supplied to MedIm following a customisation phase (i.e what else did we expect after design?)
b) The actual ann. refers to an agreement to supply devices (wearables) AFTER approval, FOR comm. launch. None of these stage-gates have been been satisfied.
c) The shipments in "this qtr" do not relate to comm. sales - per previous pt, how can they be? - the shipments/sales relate to clinical device supply. i.e to support the current studies underway.
d) As the sales relate to the above activity the recognised revenue will not be meaningful in relation to overall bal. sheet.

All of this doesnt mean the SP wont go up, but it will soon become obvious that it cannot sustain an upward move. Fundamental will kick-in.